Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia

Y Kurokawa, M Sasako, T Sano, T Yoshikawa, Y Iwasaki, A Nashimoto, S Ito, A Kurita, J Mizusawa, K Nakamura, Japan Clinical Oncology Group (JCOG9502), Y Kurokawa, M Sasako, T Sano, T Yoshikawa, Y Iwasaki, A Nashimoto, S Ito, A Kurita, J Mizusawa, K Nakamura, Japan Clinical Oncology Group (JCOG9502)

Abstract

Background: The optimal surgical approach for treatment of oesophagogastric junction (OGJ) cancer is controversial. A randomized clinical trial (JCOG9502) comparing transhiatal (TH) and left thoracoabdominal (LTA) approaches was stopped after the first interim analysis owing to limited efficacy for LTA resections. Complete 10-year follow-up data are now available.

Methods: Patients with histologically proven adenocarcinoma of the OGJ or gastric cardia with oesophageal invasion of 3 cm or less were randomized to a TH or LTA approach. Both groups underwent total gastrectomy and splenectomy with D2 nodal dissection plus para-aortic lymphadenectomy above the left renal vein. For LTA, a thorough mediastinal lymphadenectomy below the left inferior pulmonary vein was also mandatory. The primary endpoint was overall survival.

Results: A total of 167 patients (82 TH, 85 LTA) were enrolled. The 10-year overall survival rate was 37 (95 per cent c.i. 26 to 47) per cent for the TH approach and 24 (15 to 34) per cent for the LTA technique (P = 0·060). The hazard ratio for death was 1·42 (0·98 to 2·05) for the LTA technique. Subgroup analysis based on the Siewert classification indicated non-significant survival advantages in favour of the TH approach.

Conclusion: LTA resections should be avoided in the treatment of adenocarcinoma of the OGJ or gastric cardia.

Registration number: NCT00149266 (https://www.clinicaltrials.gov).

© 2015 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.

Figures

Figure 1
Figure 1
CONSORT diagram for the JCOG9502 trial. TH, transhiatal; LTA, left thoracoabdominal
Figure 2
Figure 2
Kaplan–Meier curves of a overall and b disease‐free survival in all randomized patients by treatment group. TH, transhiatal approach; LTA, left thoracoabdominal approach. a Hazard ratio (HR) 1·42 (95 per cent c.i. 0·98 to 2·05; P = 0·970 and P = 0·060, 1‐ and 2‐sided log rank test respectively); b HR 1·28 (0·87 to 1·89; P = 0·892 and P = 0·215, 1‐ and 2‐sided log rank test respectively)
Figure 3
Figure 3
Forest plot for overall survival in the subgroup analysis. *Data not available for two patients in the left thoracoabdominal (LTA) group who did not undergo surgical resection owing to M1 disease. Hazard ratios are shown with 95 per cent c.i. OGJ, oesophagogastric junction; TH, transhiatal. †Japanese Classification of Gastric Carcinoma, 12th edition16; ‡International Union Against Cancer (UICC) TNM classification, 6th edition17
Figure 4
Figure 4
Kaplan–Meier curves of overall survival in patients with a Siewert type II and b Siewert type III tumours by treatment group. TH, transhiatal approach; LTA, left thoracoabdominal approach. a Hazard ratio (HR) 1·19 (95 per cent c.i. 0·72 to 1·95; P = 0·496, 2‐sided log rank test); b HR 1·67 (0·90 to 3·11; P = 0·102, 2‐sided log rank test)

References

    1. Devesa SS, Blot WJ, Fraumeni JF Jr . Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049–2053.
    1. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549–555.
    1. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta‐analysis. Ann Thorac Surg 2001; 72: 306–313.
    1. Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction: classification, pathology and extent of resection. Dis Esoph 1996; 9: 173–182.
    1. Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K et al Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution. J Am Coll Surg 1999; 189: 594–601.
    1. Kawaura Y, Mori Y, Nakajima H, Iwa T. Total gastrectomy with left oblique abdominothoracic approach for gastric cancer involving the esophagus. Arch Surg 1988; 123: 514–518.
    1. Kodama I, Kofuji K, Yano S, Shinozaki K, Murakami N, Hori H et al Lymph node metastasis and lymphadenectomy for carcinoma in the gastric cardia: clinical experience. Int Surg 1998; 83: 205–209.
    1. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 1996; 23: 360–368.
    1. Yonemura Y, Tsugawa K, Fonseca L, Fushida S, Matsumoto H, Ninomiya I et al Lymph node metastasis and surgical management of gastric cancer invading the esophagus. Hepatogastroenterology 1995; 42: 37–42.
    1. Husemann B. Cardia carcinoma considered as a distinct entity. Br J Surg 1989; 76: 136–139.
    1. Wang LS, Wu CW, Hsieh MJ, Fahn HJ, Huang MH, Chien KY. Lymph node metastasis in patients with adenocarcinoma of gastric cardia. Cancer 1993; 71: 1948–1953.
    1. Dresner SM, Lamb PJ, Bennett MK, Hayes N, Griffin SM. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 2001; 129: 103–109.
    1. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T et al Left thoracoabdominal approach versus abdominal–transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644–651.
    1. Safranek PM, Sujendran V, Baron R, Warner N, Blesing C, Maynard ND. Oxford experience with neoadjuvant chemotherapy and surgical resection for esophageal adenocarcinomas and squamous cell tumors. Dis Esophagus 2008; 21: 201–206.
    1. Gillies RS, Simpkin A, Sgromo B, Marshall RE, Maynard ND. Left thoracoabdominal esophagectomy: results from a single specialist center. Dis Esophagus 2011; 24: 138–144.
    1. Japanese Research Society for Gastric Cancer . Japanese Classification of Gastric Carcinoma (1st English edn). Kanehara: Tokyo, 1995.
    1. Sobin LH, Wittekind C. (eds). TNM Classification of Malignant Tumours (6th edn). Wiley‐Liss: New York, 2002.
    1. Kurokawa Y, Sasako M, Sano T, Shibata T, Ito S, Nashimoto A et al Functional outcomes after extended surgery for gastric cancer. Br J Surg 2011; 98: 239–245.
    1. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H et al Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five year survival of a randomized clinical trial. Ann Surg 2007; 246: 992–1000.
    1. Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg 2011; 254: 274–280.
    1. Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y et al Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol 2012; 19: 677–683.
    1. Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg 2013; 100: 261–266.
    1. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A et al D2 lymphadenectomy alone or with para‐aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453–462.
    1. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP et al Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–2084.
    1. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al Five‐year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S‐1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387–4393.
    1. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH et al Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomized controlled trial. Lancet 2012; 379: 315–321.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel